Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan.
Djalila MekahliLisa M Guay-WoodfordMelissa A CadnapaphornchaiStuart L GoldsteinAnn DandurandHuan JiangPravin JadhavLaurie DebuquePublished in: Pediatric nephrology (Berlin, Germany) (2023)
High ratings concordance and agreement among reviewers on relevant clinical characteristics support the feasibility of pediatric risk assessment. A higher resolution version of the Graphical abstract is available as Supplementary information.